RELATED PARTY TRANSACTIONS

6 Months Ended

Sep. 30, 2021

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 4 – RELATED PARTY TRANSACTIONS

Nemaura Pharma Limited (“Pharma”), NDM Technologies Limited (“NDM”) and Black and White Health Care Limited (“B&W”) are entities controlled by the Company’s Chief Executive Officer, President, director and majority stockholder, Dewan F.H. Chowdhury. While transactions occurred during the period between the Company and Pharma, no transactions were recorded with NDM or B&W.

These unaudited condensed consolidated financial statements are intended to reflect all costs associated with the operations of DDL and TCL. Pharma has a service agreement with DDL to undertake development, manufacture, and regulatory approvals under Pharma’s ISO13485 accreditation. In lieu of these services, Pharma invoices DDL on a periodic basis for said services. Services are provided at cost plus a service surcharge amounting to less than 10% of the total costs incurred.

The table below provides a summary of activity between the Company and Pharma for the six months ended September 30, 2021 and 2020, and the year ended March 31, 2021.

	Six Months Ended September 30, 2021 (unaudited) ($)			Six Months Ended September 30, 2020 (unaudited) ($)			Year Ended March 31, 2021 ($)
Amounts due to related party at beginning of period		148,795			830,093			830,093
Amounts invoiced by Pharma to DDL (1)		1,115,748			698,300			2,441,108
Amounts invoiced by DDL to Pharma		(2,495	)		(7,060	)		(17,213	)
Amounts paid by DDL to Pharma		(1,770,942	)		(1,388,874	)		(3,209,084	)
Foreign exchange differences		5,340			21,074			103,891
Amounts due (from) / to related party at end of period		(503,554	)		153,533			148,795

(1) These amounts are primarily incurred as a result of research and development expenses charged to the Company by Pharma.